nodes	percent_of_prediction	percent_of_DWPC	metapath
Medroxyprogesterone Acetate—uterine cancer—ovarian cancer	0.456	1	CtDrD
Medroxyprogesterone Acetate—PGR—ovarian cancer	0.168	0.613	CbGaD
Medroxyprogesterone Acetate—ESR1—ovarian cancer	0.106	0.387	CbGaD
Medroxyprogesterone Acetate—AKR1C3—Doxorubicin—ovarian cancer	0.0672	0.63	CbGbCtD
Medroxyprogesterone Acetate—HSD3B2—ovarian follicle—ovarian cancer	0.0112	0.235	CbGeAlD
Medroxyprogesterone Acetate—CYP2C8—Paclitaxel—ovarian cancer	0.00986	0.0923	CbGbCtD
Medroxyprogesterone Acetate—CYP3A4—Topotecan—ovarian cancer	0.00808	0.0757	CbGbCtD
Medroxyprogesterone Acetate—CYP2C9—Paclitaxel—ovarian cancer	0.00688	0.0644	CbGbCtD
Medroxyprogesterone Acetate—CYP3A4—Vinorelbine—ovarian cancer	0.00569	0.0533	CbGbCtD
Medroxyprogesterone Acetate—PGR—corpus luteum—ovarian cancer	0.00409	0.086	CbGeAlD
Medroxyprogesterone Acetate—CYP3A4—Paclitaxel—ovarian cancer	0.004	0.0375	CbGbCtD
Medroxyprogesterone Acetate—PGR—ovarian follicle—ovarian cancer	0.0032	0.0673	CbGeAlD
Medroxyprogesterone Acetate—CYP3A4—Docetaxel—ovarian cancer	0.00289	0.0271	CbGbCtD
Medroxyprogesterone Acetate—ESR1—ovarian follicle—ovarian cancer	0.0025	0.0526	CbGeAlD
Medroxyprogesterone Acetate—CYP3A4—Doxorubicin—ovarian cancer	0.00216	0.0202	CbGbCtD
Medroxyprogesterone Acetate—PGR—oviduct—ovarian cancer	0.00141	0.0296	CbGeAlD
Medroxyprogesterone Acetate—AR—oviduct—ovarian cancer	0.00112	0.0236	CbGeAlD
Medroxyprogesterone Acetate—ESR1—oviduct—ovarian cancer	0.0011	0.0231	CbGeAlD
Medroxyprogesterone Acetate—HSD3B2—gonad—ovarian cancer	0.00103	0.0216	CbGeAlD
Medroxyprogesterone Acetate—HSD3B2—female reproductive system—ovarian cancer	0.000918	0.0193	CbGeAlD
Medroxyprogesterone Acetate—AKR1C3—Vincristine—Vinorelbine—ovarian cancer	0.000863	0.554	CbGdCrCtD
Medroxyprogesterone Acetate—HSD3B2—female gonad—ovarian cancer	0.000835	0.0176	CbGeAlD
Medroxyprogesterone Acetate—HSD3B2—testis—ovarian cancer	0.000741	0.0156	CbGeAlD
Medroxyprogesterone Acetate—AKR1C3—Vinblastine—Vinorelbine—ovarian cancer	0.000694	0.446	CbGdCrCtD
Medroxyprogesterone Acetate—AKR1C3—myometrium—ovarian cancer	0.000664	0.014	CbGeAlD
Medroxyprogesterone Acetate—HSD3B2—lymph node—ovarian cancer	0.000537	0.0113	CbGeAlD
Medroxyprogesterone Acetate—AKR1C3—uterine cervix—ovarian cancer	0.000517	0.0109	CbGeAlD
Medroxyprogesterone Acetate—AKR1C3—decidua—ovarian cancer	0.000493	0.0104	CbGeAlD
Medroxyprogesterone Acetate—AKR1C3—endometrium—ovarian cancer	0.000468	0.00983	CbGeAlD
Medroxyprogesterone Acetate—PGR—myometrium—ovarian cancer	0.00045	0.00946	CbGeAlD
Medroxyprogesterone Acetate—AKR1C3—uterus—ovarian cancer	0.000431	0.00906	CbGeAlD
Medroxyprogesterone Acetate—Dydrogesterone—PGR—ovarian cancer	0.000412	0.187	CrCbGaD
Medroxyprogesterone Acetate—AKR1C3—bone marrow—ovarian cancer	0.000366	0.00769	CbGeAlD
Medroxyprogesterone Acetate—AR—myometrium—ovarian cancer	0.000358	0.00754	CbGeAlD
Medroxyprogesterone Acetate—PGR—epithelium—ovarian cancer	0.000353	0.00742	CbGeAlD
Medroxyprogesterone Acetate—AKR1C3—female gonad—ovarian cancer	0.000352	0.00741	CbGeAlD
Medroxyprogesterone Acetate—ESR1—myometrium—ovarian cancer	0.000352	0.0074	CbGeAlD
Medroxyprogesterone Acetate—SHBG—endometrium—ovarian cancer	0.000351	0.00739	CbGeAlD
Medroxyprogesterone Acetate—AKR1C3—vagina—ovarian cancer	0.00035	0.00736	CbGeAlD
Medroxyprogesterone Acetate—PGR—uterine cervix—ovarian cancer	0.00035	0.00736	CbGeAlD
Medroxyprogesterone Acetate—Ethynodiol—PGR—ovarian cancer	0.000339	0.154	CrCbGaD
Medroxyprogesterone Acetate—ESR1—embryo—ovarian cancer	0.000338	0.00712	CbGeAlD
Medroxyprogesterone Acetate—PGR—decidua—ovarian cancer	0.000334	0.00701	CbGeAlD
Medroxyprogesterone Acetate—SHBG—gonad—ovarian cancer	0.000326	0.00685	CbGeAlD
Medroxyprogesterone Acetate—SHBG—uterus—ovarian cancer	0.000324	0.00681	CbGeAlD
Medroxyprogesterone Acetate—PGR—endometrium—ovarian cancer	0.000317	0.00666	CbGeAlD
Medroxyprogesterone Acetate—AKR1C3—testis—ovarian cancer	0.000313	0.00657	CbGeAlD
Medroxyprogesterone Acetate—PGR—uterus—ovarian cancer	0.000292	0.00613	CbGeAlD
Medroxyprogesterone Acetate—SHBG—female reproductive system—ovarian cancer	0.000291	0.00612	CbGeAlD
Medroxyprogesterone Acetate—AR—epithelium—ovarian cancer	0.000281	0.00591	CbGeAlD
Medroxyprogesterone Acetate—AR—uterine cervix—ovarian cancer	0.000279	0.00586	CbGeAlD
Medroxyprogesterone Acetate—ESR1—epithelium—ovarian cancer	0.000276	0.00581	CbGeAlD
Medroxyprogesterone Acetate—SHBG—bone marrow—ovarian cancer	0.000275	0.00578	CbGeAlD
Medroxyprogesterone Acetate—ESR1—uterine cervix—ovarian cancer	0.000274	0.00576	CbGeAlD
Medroxyprogesterone Acetate—AR—decidua—ovarian cancer	0.000266	0.00559	CbGeAlD
Medroxyprogesterone Acetate—SHBG—female gonad—ovarian cancer	0.000265	0.00557	CbGeAlD
Medroxyprogesterone Acetate—SHBG—vagina—ovarian cancer	0.000263	0.00554	CbGeAlD
Medroxyprogesterone Acetate—PGR—female reproductive system—ovarian cancer	0.000262	0.00551	CbGeAlD
Medroxyprogesterone Acetate—ESR1—decidua—ovarian cancer	0.000261	0.00548	CbGeAlD
Medroxyprogesterone Acetate—NR3C1—myometrium—ovarian cancer	0.00026	0.00546	CbGeAlD
Medroxyprogesterone Acetate—AR—endometrium—ovarian cancer	0.000252	0.0053	CbGeAlD
Medroxyprogesterone Acetate—NR3C1—embryo—ovarian cancer	0.00025	0.00525	CbGeAlD
Medroxyprogesterone Acetate—ESR1—endometrium—ovarian cancer	0.000248	0.00521	CbGeAlD
Medroxyprogesterone Acetate—Megestrol acetate—PGR—ovarian cancer	0.000248	0.112	CrCbGaD
Medroxyprogesterone Acetate—PGR—female gonad—ovarian cancer	0.000239	0.00502	CbGeAlD
Medroxyprogesterone Acetate—PGR—vagina—ovarian cancer	0.000237	0.00499	CbGeAlD
Medroxyprogesterone Acetate—SHBG—testis—ovarian cancer	0.000235	0.00494	CbGeAlD
Medroxyprogesterone Acetate—AR—gonad—ovarian cancer	0.000234	0.00492	CbGeAlD
Medroxyprogesterone Acetate—AR—uterus—ovarian cancer	0.000232	0.00489	CbGeAlD
Medroxyprogesterone Acetate—ESR1—gonad—ovarian cancer	0.00023	0.00483	CbGeAlD
Medroxyprogesterone Acetate—ESR1—uterus—ovarian cancer	0.000228	0.0048	CbGeAlD
Medroxyprogesterone Acetate—AKR1C3—lymph node—ovarian cancer	0.000227	0.00476	CbGeAlD
Medroxyprogesterone Acetate—Drospirenone—PGR—ovarian cancer	0.000216	0.098	CrCbGaD
Medroxyprogesterone Acetate—Ethynodiol—ESR1—ovarian cancer	0.000214	0.097	CrCbGaD
Medroxyprogesterone Acetate—PGR—testis—ovarian cancer	0.000212	0.00445	CbGeAlD
Medroxyprogesterone Acetate—AR—female reproductive system—ovarian cancer	0.000209	0.00439	CbGeAlD
Medroxyprogesterone Acetate—ESR1—female reproductive system—ovarian cancer	0.000205	0.00431	CbGeAlD
Medroxyprogesterone Acetate—CYP2C8—endometrium—ovarian cancer	0.000204	0.00429	CbGeAlD
Medroxyprogesterone Acetate—NR3C1—epithelium—ovarian cancer	0.000204	0.00428	CbGeAlD
Medroxyprogesterone Acetate—NR3C1—uterine cervix—ovarian cancer	0.000202	0.00425	CbGeAlD
Medroxyprogesterone Acetate—NR3C1—decidua—ovarian cancer	0.000192	0.00405	CbGeAlD
Medroxyprogesterone Acetate—AR—female gonad—ovarian cancer	0.00019	0.004	CbGeAlD
Medroxyprogesterone Acetate—AR—vagina—ovarian cancer	0.000189	0.00397	CbGeAlD
Medroxyprogesterone Acetate—ESR1—female gonad—ovarian cancer	0.000187	0.00392	CbGeAlD
Medroxyprogesterone Acetate—ESR1—vagina—ovarian cancer	0.000186	0.0039	CbGeAlD
Medroxyprogesterone Acetate—NR3C1—endometrium—ovarian cancer	0.000183	0.00384	CbGeAlD
Medroxyprogesterone Acetate—NR3C1—gonad—ovarian cancer	0.000169	0.00356	CbGeAlD
Medroxyprogesterone Acetate—CYP2C8—female reproductive system—ovarian cancer	0.000169	0.00355	CbGeAlD
Medroxyprogesterone Acetate—AR—testis—ovarian cancer	0.000169	0.00355	CbGeAlD
Medroxyprogesterone Acetate—NR3C1—uterus—ovarian cancer	0.000168	0.00354	CbGeAlD
Medroxyprogesterone Acetate—ESR1—testis—ovarian cancer	0.000166	0.00348	CbGeAlD
Medroxyprogesterone Acetate—Spironolactone—PGR—ovarian cancer	0.000154	0.0698	CrCbGaD
Medroxyprogesterone Acetate—PGR—lymph node—ovarian cancer	0.000153	0.00323	CbGeAlD
Medroxyprogesterone Acetate—CYP2C8—vagina—ovarian cancer	0.000153	0.00321	CbGeAlD
Medroxyprogesterone Acetate—NR3C1—female reproductive system—ovarian cancer	0.000151	0.00318	CbGeAlD
Medroxyprogesterone Acetate—CYP2C9—female reproductive system—ovarian cancer	0.00015	0.00316	CbGeAlD
Medroxyprogesterone Acetate—NR3C1—bone marrow—ovarian cancer	0.000143	0.003	CbGeAlD
Medroxyprogesterone Acetate—NR3C1—female gonad—ovarian cancer	0.000138	0.0029	CbGeAlD
Medroxyprogesterone Acetate—NR3C1—vagina—ovarian cancer	0.000137	0.00288	CbGeAlD
Medroxyprogesterone Acetate—CYP2C8—testis—ovarian cancer	0.000136	0.00287	CbGeAlD
Medroxyprogesterone Acetate—AR—lymph node—ovarian cancer	0.000122	0.00257	CbGeAlD
Medroxyprogesterone Acetate—NR3C1—testis—ovarian cancer	0.000122	0.00257	CbGeAlD
Medroxyprogesterone Acetate—ESR1—lymph node—ovarian cancer	0.00012	0.00252	CbGeAlD
Medroxyprogesterone Acetate—CYP3A4—female reproductive system—ovarian cancer	0.000114	0.00241	CbGeAlD
Medroxyprogesterone Acetate—Fluoxymesterone—ESR1—ovarian cancer	0.000106	0.0481	CrCbGaD
Medroxyprogesterone Acetate—NR3C1—lymph node—ovarian cancer	8.85e-05	0.00186	CbGeAlD
Medroxyprogesterone Acetate—Progesterone—PGR—ovarian cancer	8.33e-05	0.0378	CrCbGaD
Medroxyprogesterone Acetate—Progesterone—CYP1B1—ovarian cancer	7.79e-05	0.0353	CrCbGaD
Medroxyprogesterone Acetate—Testosterone—CYP1B1—ovarian cancer	7.36e-05	0.0334	CrCbGaD
Medroxyprogesterone Acetate—Megestrol acetate—ABCB1—ovarian cancer	6.64e-05	0.0301	CrCbGaD
Medroxyprogesterone Acetate—Progesterone—ESR1—ovarian cancer	5.26e-05	0.0238	CrCbGaD
Medroxyprogesterone Acetate—Methylprednisolone—ABCB1—ovarian cancer	5.09e-05	0.0231	CrCbGaD
Medroxyprogesterone Acetate—Spironolactone—ABCB1—ovarian cancer	4.13e-05	0.0187	CrCbGaD
Medroxyprogesterone Acetate—Dyspnoea—Paclitaxel—ovarian cancer	3.24e-05	0.000421	CcSEcCtD
Medroxyprogesterone Acetate—Somnolence—Paclitaxel—ovarian cancer	3.23e-05	0.00042	CcSEcCtD
Medroxyprogesterone Acetate—Myalgia—Docetaxel—ovarian cancer	3.21e-05	0.000418	CcSEcCtD
Medroxyprogesterone Acetate—Arthralgia—Docetaxel—ovarian cancer	3.21e-05	0.000418	CcSEcCtD
Medroxyprogesterone Acetate—Chest pain—Docetaxel—ovarian cancer	3.21e-05	0.000418	CcSEcCtD
Medroxyprogesterone Acetate—Nausea—Vinorelbine—ovarian cancer	3.21e-05	0.000417	CcSEcCtD
Medroxyprogesterone Acetate—Dyspepsia—Paclitaxel—ovarian cancer	3.2e-05	0.000416	CcSEcCtD
Medroxyprogesterone Acetate—Neuropathy peripheral—Epirubicin—ovarian cancer	3.19e-05	0.000415	CcSEcCtD
Medroxyprogesterone Acetate—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—ovarian cancer	3.19e-05	0.000415	CcSEcCtD
Medroxyprogesterone Acetate—Stomatitis—Epirubicin—ovarian cancer	3.18e-05	0.000413	CcSEcCtD
Medroxyprogesterone Acetate—Jaundice—Epirubicin—ovarian cancer	3.18e-05	0.000413	CcSEcCtD
Medroxyprogesterone Acetate—Urinary tract infection—Epirubicin—ovarian cancer	3.17e-05	0.000412	CcSEcCtD
Medroxyprogesterone Acetate—Dysuria—Doxorubicin—ovarian cancer	3.16e-05	0.000411	CcSEcCtD
Medroxyprogesterone Acetate—Decreased appetite—Paclitaxel—ovarian cancer	3.16e-05	0.000411	CcSEcCtD
Medroxyprogesterone Acetate—Dry mouth—Docetaxel—ovarian cancer	3.14e-05	0.000409	CcSEcCtD
Medroxyprogesterone Acetate—Upper respiratory tract infection—Doxorubicin—ovarian cancer	3.14e-05	0.000409	CcSEcCtD
Medroxyprogesterone Acetate—Gastrointestinal disorder—Paclitaxel—ovarian cancer	3.14e-05	0.000408	CcSEcCtD
Medroxyprogesterone Acetate—Fatigue—Paclitaxel—ovarian cancer	3.13e-05	0.000407	CcSEcCtD
Medroxyprogesterone Acetate—Sweating—Epirubicin—ovarian cancer	3.12e-05	0.000406	CcSEcCtD
Medroxyprogesterone Acetate—Pollakiuria—Doxorubicin—ovarian cancer	3.12e-05	0.000406	CcSEcCtD
Medroxyprogesterone Acetate—Constipation—Paclitaxel—ovarian cancer	3.11e-05	0.000404	CcSEcCtD
Medroxyprogesterone Acetate—Confusional state—Docetaxel—ovarian cancer	3.11e-05	0.000404	CcSEcCtD
Medroxyprogesterone Acetate—Hepatobiliary disease—Epirubicin—ovarian cancer	3.08e-05	0.000401	CcSEcCtD
Medroxyprogesterone Acetate—Anaphylactic shock—Docetaxel—ovarian cancer	3.08e-05	0.000401	CcSEcCtD
Medroxyprogesterone Acetate—Oedema—Docetaxel—ovarian cancer	3.08e-05	0.000401	CcSEcCtD
Medroxyprogesterone Acetate—Weight increased—Doxorubicin—ovarian cancer	3.08e-05	0.0004	CcSEcCtD
Medroxyprogesterone Acetate—Epistaxis—Epirubicin—ovarian cancer	3.07e-05	0.0004	CcSEcCtD
Medroxyprogesterone Acetate—Infection—Docetaxel—ovarian cancer	3.06e-05	0.000398	CcSEcCtD
Medroxyprogesterone Acetate—Weight decreased—Doxorubicin—ovarian cancer	3.06e-05	0.000398	CcSEcCtD
Medroxyprogesterone Acetate—Sinusitis—Epirubicin—ovarian cancer	3.06e-05	0.000397	CcSEcCtD
Medroxyprogesterone Acetate—Hyperglycaemia—Doxorubicin—ovarian cancer	3.05e-05	0.000397	CcSEcCtD
Medroxyprogesterone Acetate—Shock—Docetaxel—ovarian cancer	3.03e-05	0.000394	CcSEcCtD
Medroxyprogesterone Acetate—Nervous system disorder—Docetaxel—ovarian cancer	3.02e-05	0.000393	CcSEcCtD
Medroxyprogesterone Acetate—Thrombocytopenia—Docetaxel—ovarian cancer	3.02e-05	0.000392	CcSEcCtD
Medroxyprogesterone Acetate—Infestation—Doxorubicin—ovarian cancer	3.02e-05	0.000392	CcSEcCtD
Medroxyprogesterone Acetate—Infestation NOS—Doxorubicin—ovarian cancer	3.02e-05	0.000392	CcSEcCtD
Medroxyprogesterone Acetate—Drowsiness—Doxorubicin—ovarian cancer	3.02e-05	0.000392	CcSEcCtD
Medroxyprogesterone Acetate—Tachycardia—Docetaxel—ovarian cancer	3.01e-05	0.000391	CcSEcCtD
Medroxyprogesterone Acetate—Feeling abnormal—Paclitaxel—ovarian cancer	3e-05	0.000389	CcSEcCtD
Medroxyprogesterone Acetate—Skin disorder—Docetaxel—ovarian cancer	2.99e-05	0.000389	CcSEcCtD
Medroxyprogesterone Acetate—Bradycardia—Epirubicin—ovarian cancer	2.98e-05	0.000387	CcSEcCtD
Medroxyprogesterone Acetate—Gastrointestinal pain—Paclitaxel—ovarian cancer	2.97e-05	0.000386	CcSEcCtD
Medroxyprogesterone Acetate—Neuropathy peripheral—Doxorubicin—ovarian cancer	2.96e-05	0.000384	CcSEcCtD
Medroxyprogesterone Acetate—Haemoglobin—Epirubicin—ovarian cancer	2.94e-05	0.000382	CcSEcCtD
Medroxyprogesterone Acetate—Jaundice—Doxorubicin—ovarian cancer	2.94e-05	0.000382	CcSEcCtD
Medroxyprogesterone Acetate—Stomatitis—Doxorubicin—ovarian cancer	2.94e-05	0.000382	CcSEcCtD
Medroxyprogesterone Acetate—Anorexia—Docetaxel—ovarian cancer	2.94e-05	0.000382	CcSEcCtD
Medroxyprogesterone Acetate—Urinary tract infection—Doxorubicin—ovarian cancer	2.93e-05	0.000381	CcSEcCtD
Medroxyprogesterone Acetate—Hepatitis—Epirubicin—ovarian cancer	2.93e-05	0.00038	CcSEcCtD
Medroxyprogesterone Acetate—Haemorrhage—Epirubicin—ovarian cancer	2.93e-05	0.00038	CcSEcCtD
Medroxyprogesterone Acetate—Pharyngitis—Epirubicin—ovarian cancer	2.9e-05	0.000377	CcSEcCtD
Medroxyprogesterone Acetate—Sweating—Doxorubicin—ovarian cancer	2.89e-05	0.000376	CcSEcCtD
Medroxyprogesterone Acetate—Urinary tract disorder—Epirubicin—ovarian cancer	2.89e-05	0.000376	CcSEcCtD
Medroxyprogesterone Acetate—Urticaria—Paclitaxel—ovarian cancer	2.89e-05	0.000375	CcSEcCtD
Medroxyprogesterone Acetate—Oedema peripheral—Epirubicin—ovarian cancer	2.88e-05	0.000375	CcSEcCtD
Medroxyprogesterone Acetate—Hypotension—Docetaxel—ovarian cancer	2.88e-05	0.000374	CcSEcCtD
Medroxyprogesterone Acetate—Connective tissue disorder—Epirubicin—ovarian cancer	2.87e-05	0.000374	CcSEcCtD
Medroxyprogesterone Acetate—Abdominal pain—Paclitaxel—ovarian cancer	2.87e-05	0.000374	CcSEcCtD
Medroxyprogesterone Acetate—Body temperature increased—Paclitaxel—ovarian cancer	2.87e-05	0.000374	CcSEcCtD
Medroxyprogesterone Acetate—Urethral disorder—Epirubicin—ovarian cancer	2.87e-05	0.000373	CcSEcCtD
Medroxyprogesterone Acetate—Hepatobiliary disease—Doxorubicin—ovarian cancer	2.85e-05	0.000371	CcSEcCtD
Medroxyprogesterone Acetate—Epistaxis—Doxorubicin—ovarian cancer	2.84e-05	0.00037	CcSEcCtD
Medroxyprogesterone Acetate—Sinusitis—Doxorubicin—ovarian cancer	2.83e-05	0.000368	CcSEcCtD
Medroxyprogesterone Acetate—Visual impairment—Epirubicin—ovarian cancer	2.82e-05	0.000367	CcSEcCtD
Medroxyprogesterone Acetate—Musculoskeletal discomfort—Docetaxel—ovarian cancer	2.81e-05	0.000365	CcSEcCtD
Medroxyprogesterone Acetate—Insomnia—Docetaxel—ovarian cancer	2.79e-05	0.000362	CcSEcCtD
Medroxyprogesterone Acetate—Paraesthesia—Docetaxel—ovarian cancer	2.77e-05	0.00036	CcSEcCtD
Medroxyprogesterone Acetate—Erythema multiforme—Epirubicin—ovarian cancer	2.77e-05	0.00036	CcSEcCtD
Medroxyprogesterone Acetate—Bradycardia—Doxorubicin—ovarian cancer	2.76e-05	0.000358	CcSEcCtD
Medroxyprogesterone Acetate—Dyspnoea—Docetaxel—ovarian cancer	2.75e-05	0.000357	CcSEcCtD
Medroxyprogesterone Acetate—Hydrocortisone—ABCB1—ovarian cancer	2.74e-05	0.0124	CrCbGaD
Medroxyprogesterone Acetate—Somnolence—Docetaxel—ovarian cancer	2.74e-05	0.000356	CcSEcCtD
Medroxyprogesterone Acetate—Eye disorder—Epirubicin—ovarian cancer	2.73e-05	0.000355	CcSEcCtD
Medroxyprogesterone Acetate—Tinnitus—Epirubicin—ovarian cancer	2.73e-05	0.000355	CcSEcCtD
Medroxyprogesterone Acetate—Haemoglobin—Doxorubicin—ovarian cancer	2.72e-05	0.000354	CcSEcCtD
Medroxyprogesterone Acetate—Cardiac disorder—Epirubicin—ovarian cancer	2.72e-05	0.000353	CcSEcCtD
Medroxyprogesterone Acetate—Dyspepsia—Docetaxel—ovarian cancer	2.71e-05	0.000353	CcSEcCtD
Medroxyprogesterone Acetate—Haemorrhage—Doxorubicin—ovarian cancer	2.71e-05	0.000352	CcSEcCtD
Medroxyprogesterone Acetate—Hepatitis—Doxorubicin—ovarian cancer	2.71e-05	0.000352	CcSEcCtD
Medroxyprogesterone Acetate—Pharyngitis—Doxorubicin—ovarian cancer	2.69e-05	0.000349	CcSEcCtD
Medroxyprogesterone Acetate—Decreased appetite—Docetaxel—ovarian cancer	2.68e-05	0.000348	CcSEcCtD
Medroxyprogesterone Acetate—Hypersensitivity—Paclitaxel—ovarian cancer	2.68e-05	0.000348	CcSEcCtD
Medroxyprogesterone Acetate—Urinary tract disorder—Doxorubicin—ovarian cancer	2.67e-05	0.000348	CcSEcCtD
Medroxyprogesterone Acetate—Oedema peripheral—Doxorubicin—ovarian cancer	2.67e-05	0.000347	CcSEcCtD
Medroxyprogesterone Acetate—Gastrointestinal disorder—Docetaxel—ovarian cancer	2.66e-05	0.000346	CcSEcCtD
Medroxyprogesterone Acetate—Connective tissue disorder—Doxorubicin—ovarian cancer	2.66e-05	0.000346	CcSEcCtD
Medroxyprogesterone Acetate—Fatigue—Docetaxel—ovarian cancer	2.66e-05	0.000345	CcSEcCtD
Medroxyprogesterone Acetate—Angiopathy—Epirubicin—ovarian cancer	2.65e-05	0.000345	CcSEcCtD
Medroxyprogesterone Acetate—Urethral disorder—Doxorubicin—ovarian cancer	2.65e-05	0.000345	CcSEcCtD
Medroxyprogesterone Acetate—Immune system disorder—Epirubicin—ovarian cancer	2.64e-05	0.000344	CcSEcCtD
Medroxyprogesterone Acetate—Mediastinal disorder—Epirubicin—ovarian cancer	2.64e-05	0.000343	CcSEcCtD
Medroxyprogesterone Acetate—Constipation—Docetaxel—ovarian cancer	2.64e-05	0.000343	CcSEcCtD
Medroxyprogesterone Acetate—Chills—Epirubicin—ovarian cancer	2.62e-05	0.000341	CcSEcCtD
Medroxyprogesterone Acetate—Visual impairment—Doxorubicin—ovarian cancer	2.61e-05	0.000339	CcSEcCtD
Medroxyprogesterone Acetate—Asthenia—Paclitaxel—ovarian cancer	2.61e-05	0.000339	CcSEcCtD
Medroxyprogesterone Acetate—Alopecia—Epirubicin—ovarian cancer	2.59e-05	0.000336	CcSEcCtD
Medroxyprogesterone Acetate—Pruritus—Paclitaxel—ovarian cancer	2.57e-05	0.000334	CcSEcCtD
Medroxyprogesterone Acetate—Mental disorder—Epirubicin—ovarian cancer	2.56e-05	0.000333	CcSEcCtD
Medroxyprogesterone Acetate—Erythema multiforme—Doxorubicin—ovarian cancer	2.56e-05	0.000333	CcSEcCtD
Medroxyprogesterone Acetate—Erythema—Epirubicin—ovarian cancer	2.55e-05	0.000331	CcSEcCtD
Medroxyprogesterone Acetate—Malnutrition—Epirubicin—ovarian cancer	2.55e-05	0.000331	CcSEcCtD
Medroxyprogesterone Acetate—Feeling abnormal—Docetaxel—ovarian cancer	2.54e-05	0.00033	CcSEcCtD
Medroxyprogesterone Acetate—Eye disorder—Doxorubicin—ovarian cancer	2.53e-05	0.000329	CcSEcCtD
Medroxyprogesterone Acetate—Tinnitus—Doxorubicin—ovarian cancer	2.52e-05	0.000328	CcSEcCtD
Medroxyprogesterone Acetate—Gastrointestinal pain—Docetaxel—ovarian cancer	2.52e-05	0.000328	CcSEcCtD
Medroxyprogesterone Acetate—Cardiac disorder—Doxorubicin—ovarian cancer	2.51e-05	0.000327	CcSEcCtD
Medroxyprogesterone Acetate—Flatulence—Epirubicin—ovarian cancer	2.51e-05	0.000326	CcSEcCtD
Medroxyprogesterone Acetate—Tension—Epirubicin—ovarian cancer	2.5e-05	0.000325	CcSEcCtD
Medroxyprogesterone Acetate—Dysgeusia—Epirubicin—ovarian cancer	2.49e-05	0.000324	CcSEcCtD
Medroxyprogesterone Acetate—Diarrhoea—Paclitaxel—ovarian cancer	2.49e-05	0.000323	CcSEcCtD
Medroxyprogesterone Acetate—Nervousness—Epirubicin—ovarian cancer	2.47e-05	0.000322	CcSEcCtD
Medroxyprogesterone Acetate—Back pain—Epirubicin—ovarian cancer	2.46e-05	0.00032	CcSEcCtD
Medroxyprogesterone Acetate—Angiopathy—Doxorubicin—ovarian cancer	2.46e-05	0.000319	CcSEcCtD
Medroxyprogesterone Acetate—Muscle spasms—Epirubicin—ovarian cancer	2.45e-05	0.000318	CcSEcCtD
Medroxyprogesterone Acetate—Immune system disorder—Doxorubicin—ovarian cancer	2.45e-05	0.000318	CcSEcCtD
Medroxyprogesterone Acetate—Mediastinal disorder—Doxorubicin—ovarian cancer	2.44e-05	0.000317	CcSEcCtD
Medroxyprogesterone Acetate—Abdominal pain—Docetaxel—ovarian cancer	2.44e-05	0.000317	CcSEcCtD
Medroxyprogesterone Acetate—Body temperature increased—Docetaxel—ovarian cancer	2.44e-05	0.000317	CcSEcCtD
Medroxyprogesterone Acetate—Chills—Doxorubicin—ovarian cancer	2.43e-05	0.000316	CcSEcCtD
Medroxyprogesterone Acetate—Dizziness—Paclitaxel—ovarian cancer	2.4e-05	0.000313	CcSEcCtD
Medroxyprogesterone Acetate—Alopecia—Doxorubicin—ovarian cancer	2.39e-05	0.000311	CcSEcCtD
Medroxyprogesterone Acetate—Mental disorder—Doxorubicin—ovarian cancer	2.37e-05	0.000308	CcSEcCtD
Medroxyprogesterone Acetate—Ill-defined disorder—Epirubicin—ovarian cancer	2.36e-05	0.000307	CcSEcCtD
Medroxyprogesterone Acetate—Erythema—Doxorubicin—ovarian cancer	2.36e-05	0.000306	CcSEcCtD
Medroxyprogesterone Acetate—Malnutrition—Doxorubicin—ovarian cancer	2.36e-05	0.000306	CcSEcCtD
Medroxyprogesterone Acetate—Anaemia—Epirubicin—ovarian cancer	2.35e-05	0.000306	CcSEcCtD
Medroxyprogesterone Acetate—Agitation—Epirubicin—ovarian cancer	2.34e-05	0.000304	CcSEcCtD
Medroxyprogesterone Acetate—Flatulence—Doxorubicin—ovarian cancer	2.32e-05	0.000302	CcSEcCtD
Medroxyprogesterone Acetate—Tension—Doxorubicin—ovarian cancer	2.31e-05	0.000301	CcSEcCtD
Medroxyprogesterone Acetate—Vomiting—Paclitaxel—ovarian cancer	2.31e-05	0.000301	CcSEcCtD
Medroxyprogesterone Acetate—Dysgeusia—Doxorubicin—ovarian cancer	2.31e-05	0.0003	CcSEcCtD
Medroxyprogesterone Acetate—Malaise—Epirubicin—ovarian cancer	2.3e-05	0.000299	CcSEcCtD
Medroxyprogesterone Acetate—Rash—Paclitaxel—ovarian cancer	2.29e-05	0.000298	CcSEcCtD
Medroxyprogesterone Acetate—Dermatitis—Paclitaxel—ovarian cancer	2.29e-05	0.000298	CcSEcCtD
Medroxyprogesterone Acetate—Nervousness—Doxorubicin—ovarian cancer	2.29e-05	0.000298	CcSEcCtD
Medroxyprogesterone Acetate—Vertigo—Epirubicin—ovarian cancer	2.29e-05	0.000297	CcSEcCtD
Medroxyprogesterone Acetate—Syncope—Epirubicin—ovarian cancer	2.28e-05	0.000297	CcSEcCtD
Medroxyprogesterone Acetate—Back pain—Doxorubicin—ovarian cancer	2.28e-05	0.000296	CcSEcCtD
Medroxyprogesterone Acetate—Headache—Paclitaxel—ovarian cancer	2.28e-05	0.000296	CcSEcCtD
Medroxyprogesterone Acetate—Hypersensitivity—Docetaxel—ovarian cancer	2.27e-05	0.000295	CcSEcCtD
Medroxyprogesterone Acetate—Muscle spasms—Doxorubicin—ovarian cancer	2.27e-05	0.000295	CcSEcCtD
Medroxyprogesterone Acetate—Palpitations—Epirubicin—ovarian cancer	2.25e-05	0.000293	CcSEcCtD
Medroxyprogesterone Acetate—Loss of consciousness—Epirubicin—ovarian cancer	2.24e-05	0.000291	CcSEcCtD
Medroxyprogesterone Acetate—Progesterone—ABCB1—ovarian cancer	2.23e-05	0.0101	CrCbGaD
Medroxyprogesterone Acetate—Asthenia—Docetaxel—ovarian cancer	2.21e-05	0.000287	CcSEcCtD
Medroxyprogesterone Acetate—Convulsion—Epirubicin—ovarian cancer	2.21e-05	0.000287	CcSEcCtD
Medroxyprogesterone Acetate—Ill-defined disorder—Doxorubicin—ovarian cancer	2.19e-05	0.000284	CcSEcCtD
Medroxyprogesterone Acetate—Pruritus—Docetaxel—ovarian cancer	2.18e-05	0.000283	CcSEcCtD
Medroxyprogesterone Acetate—Anaemia—Doxorubicin—ovarian cancer	2.18e-05	0.000283	CcSEcCtD
Medroxyprogesterone Acetate—Myalgia—Epirubicin—ovarian cancer	2.17e-05	0.000282	CcSEcCtD
Medroxyprogesterone Acetate—Arthralgia—Epirubicin—ovarian cancer	2.17e-05	0.000282	CcSEcCtD
Medroxyprogesterone Acetate—Chest pain—Epirubicin—ovarian cancer	2.17e-05	0.000282	CcSEcCtD
Medroxyprogesterone Acetate—Agitation—Doxorubicin—ovarian cancer	2.17e-05	0.000282	CcSEcCtD
Medroxyprogesterone Acetate—Anxiety—Epirubicin—ovarian cancer	2.16e-05	0.000281	CcSEcCtD
Medroxyprogesterone Acetate—Nausea—Paclitaxel—ovarian cancer	2.16e-05	0.000281	CcSEcCtD
Medroxyprogesterone Acetate—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—ovarian cancer	2.15e-05	0.00028	CcSEcCtD
Medroxyprogesterone Acetate—Discomfort—Epirubicin—ovarian cancer	2.14e-05	0.000278	CcSEcCtD
Medroxyprogesterone Acetate—Malaise—Doxorubicin—ovarian cancer	2.12e-05	0.000276	CcSEcCtD
Medroxyprogesterone Acetate—Dry mouth—Epirubicin—ovarian cancer	2.12e-05	0.000276	CcSEcCtD
Medroxyprogesterone Acetate—Vertigo—Doxorubicin—ovarian cancer	2.12e-05	0.000275	CcSEcCtD
Medroxyprogesterone Acetate—Syncope—Doxorubicin—ovarian cancer	2.11e-05	0.000275	CcSEcCtD
Medroxyprogesterone Acetate—Testosterone—ABCB1—ovarian cancer	2.11e-05	0.00958	CrCbGaD
Medroxyprogesterone Acetate—Diarrhoea—Docetaxel—ovarian cancer	2.11e-05	0.000274	CcSEcCtD
Medroxyprogesterone Acetate—Confusional state—Epirubicin—ovarian cancer	2.1e-05	0.000272	CcSEcCtD
Medroxyprogesterone Acetate—Palpitations—Doxorubicin—ovarian cancer	2.08e-05	0.000271	CcSEcCtD
Medroxyprogesterone Acetate—Oedema—Epirubicin—ovarian cancer	2.08e-05	0.00027	CcSEcCtD
Medroxyprogesterone Acetate—Anaphylactic shock—Epirubicin—ovarian cancer	2.08e-05	0.00027	CcSEcCtD
Medroxyprogesterone Acetate—Loss of consciousness—Doxorubicin—ovarian cancer	2.07e-05	0.000269	CcSEcCtD
Medroxyprogesterone Acetate—Infection—Epirubicin—ovarian cancer	2.06e-05	0.000268	CcSEcCtD
Medroxyprogesterone Acetate—Shock—Epirubicin—ovarian cancer	2.04e-05	0.000266	CcSEcCtD
Medroxyprogesterone Acetate—Convulsion—Doxorubicin—ovarian cancer	2.04e-05	0.000265	CcSEcCtD
Medroxyprogesterone Acetate—Nervous system disorder—Epirubicin—ovarian cancer	2.04e-05	0.000265	CcSEcCtD
Medroxyprogesterone Acetate—Dizziness—Docetaxel—ovarian cancer	2.04e-05	0.000265	CcSEcCtD
Medroxyprogesterone Acetate—Thrombocytopenia—Epirubicin—ovarian cancer	2.04e-05	0.000265	CcSEcCtD
Medroxyprogesterone Acetate—Tachycardia—Epirubicin—ovarian cancer	2.03e-05	0.000264	CcSEcCtD
Medroxyprogesterone Acetate—Skin disorder—Epirubicin—ovarian cancer	2.02e-05	0.000262	CcSEcCtD
Medroxyprogesterone Acetate—Hyperhidrosis—Epirubicin—ovarian cancer	2.01e-05	0.000261	CcSEcCtD
Medroxyprogesterone Acetate—Arthralgia—Doxorubicin—ovarian cancer	2.01e-05	0.000261	CcSEcCtD
Medroxyprogesterone Acetate—Chest pain—Doxorubicin—ovarian cancer	2.01e-05	0.000261	CcSEcCtD
Medroxyprogesterone Acetate—Myalgia—Doxorubicin—ovarian cancer	2.01e-05	0.000261	CcSEcCtD
Medroxyprogesterone Acetate—Anxiety—Doxorubicin—ovarian cancer	2e-05	0.00026	CcSEcCtD
Medroxyprogesterone Acetate—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—ovarian cancer	1.99e-05	0.000259	CcSEcCtD
Medroxyprogesterone Acetate—Discomfort—Doxorubicin—ovarian cancer	1.98e-05	0.000258	CcSEcCtD
Medroxyprogesterone Acetate—Anorexia—Epirubicin—ovarian cancer	1.98e-05	0.000258	CcSEcCtD
Medroxyprogesterone Acetate—Dry mouth—Doxorubicin—ovarian cancer	1.96e-05	0.000255	CcSEcCtD
Medroxyprogesterone Acetate—Vomiting—Docetaxel—ovarian cancer	1.96e-05	0.000255	CcSEcCtD
Medroxyprogesterone Acetate—Rash—Docetaxel—ovarian cancer	1.94e-05	0.000253	CcSEcCtD
Medroxyprogesterone Acetate—Hypotension—Epirubicin—ovarian cancer	1.94e-05	0.000252	CcSEcCtD
Medroxyprogesterone Acetate—Dermatitis—Docetaxel—ovarian cancer	1.94e-05	0.000252	CcSEcCtD
Medroxyprogesterone Acetate—Confusional state—Doxorubicin—ovarian cancer	1.94e-05	0.000252	CcSEcCtD
Medroxyprogesterone Acetate—Headache—Docetaxel—ovarian cancer	1.93e-05	0.000251	CcSEcCtD
Medroxyprogesterone Acetate—Oedema—Doxorubicin—ovarian cancer	1.92e-05	0.00025	CcSEcCtD
Medroxyprogesterone Acetate—Anaphylactic shock—Doxorubicin—ovarian cancer	1.92e-05	0.00025	CcSEcCtD
Medroxyprogesterone Acetate—Infection—Doxorubicin—ovarian cancer	1.91e-05	0.000248	CcSEcCtD
Medroxyprogesterone Acetate—Musculoskeletal discomfort—Epirubicin—ovarian cancer	1.89e-05	0.000246	CcSEcCtD
Medroxyprogesterone Acetate—Shock—Doxorubicin—ovarian cancer	1.89e-05	0.000246	CcSEcCtD
Medroxyprogesterone Acetate—Nervous system disorder—Doxorubicin—ovarian cancer	1.89e-05	0.000245	CcSEcCtD
Medroxyprogesterone Acetate—Thrombocytopenia—Doxorubicin—ovarian cancer	1.88e-05	0.000245	CcSEcCtD
Medroxyprogesterone Acetate—Insomnia—Epirubicin—ovarian cancer	1.88e-05	0.000244	CcSEcCtD
Medroxyprogesterone Acetate—Tachycardia—Doxorubicin—ovarian cancer	1.88e-05	0.000244	CcSEcCtD
Medroxyprogesterone Acetate—Skin disorder—Doxorubicin—ovarian cancer	1.87e-05	0.000243	CcSEcCtD
Medroxyprogesterone Acetate—Paraesthesia—Epirubicin—ovarian cancer	1.87e-05	0.000243	CcSEcCtD
Medroxyprogesterone Acetate—Hyperhidrosis—Doxorubicin—ovarian cancer	1.86e-05	0.000242	CcSEcCtD
Medroxyprogesterone Acetate—Dyspnoea—Epirubicin—ovarian cancer	1.85e-05	0.000241	CcSEcCtD
Medroxyprogesterone Acetate—Somnolence—Epirubicin—ovarian cancer	1.85e-05	0.00024	CcSEcCtD
Medroxyprogesterone Acetate—Anorexia—Doxorubicin—ovarian cancer	1.83e-05	0.000238	CcSEcCtD
Medroxyprogesterone Acetate—Nausea—Docetaxel—ovarian cancer	1.83e-05	0.000238	CcSEcCtD
Medroxyprogesterone Acetate—Dyspepsia—Epirubicin—ovarian cancer	1.83e-05	0.000238	CcSEcCtD
Medroxyprogesterone Acetate—Decreased appetite—Epirubicin—ovarian cancer	1.81e-05	0.000235	CcSEcCtD
Medroxyprogesterone Acetate—Hypotension—Doxorubicin—ovarian cancer	1.8e-05	0.000234	CcSEcCtD
Medroxyprogesterone Acetate—Gastrointestinal disorder—Epirubicin—ovarian cancer	1.79e-05	0.000233	CcSEcCtD
Medroxyprogesterone Acetate—Fatigue—Epirubicin—ovarian cancer	1.79e-05	0.000233	CcSEcCtD
Medroxyprogesterone Acetate—Constipation—Epirubicin—ovarian cancer	1.78e-05	0.000231	CcSEcCtD
Medroxyprogesterone Acetate—Musculoskeletal discomfort—Doxorubicin—ovarian cancer	1.75e-05	0.000228	CcSEcCtD
Medroxyprogesterone Acetate—Insomnia—Doxorubicin—ovarian cancer	1.74e-05	0.000226	CcSEcCtD
Medroxyprogesterone Acetate—Paraesthesia—Doxorubicin—ovarian cancer	1.73e-05	0.000225	CcSEcCtD
Medroxyprogesterone Acetate—Dyspnoea—Doxorubicin—ovarian cancer	1.71e-05	0.000223	CcSEcCtD
Medroxyprogesterone Acetate—Feeling abnormal—Epirubicin—ovarian cancer	1.71e-05	0.000223	CcSEcCtD
Medroxyprogesterone Acetate—Somnolence—Doxorubicin—ovarian cancer	1.71e-05	0.000222	CcSEcCtD
Medroxyprogesterone Acetate—Gastrointestinal pain—Epirubicin—ovarian cancer	1.7e-05	0.000221	CcSEcCtD
Medroxyprogesterone Acetate—Dyspepsia—Doxorubicin—ovarian cancer	1.69e-05	0.00022	CcSEcCtD
Medroxyprogesterone Acetate—Decreased appetite—Doxorubicin—ovarian cancer	1.67e-05	0.000217	CcSEcCtD
Medroxyprogesterone Acetate—Gastrointestinal disorder—Doxorubicin—ovarian cancer	1.66e-05	0.000216	CcSEcCtD
Medroxyprogesterone Acetate—Fatigue—Doxorubicin—ovarian cancer	1.66e-05	0.000216	CcSEcCtD
Medroxyprogesterone Acetate—Urticaria—Epirubicin—ovarian cancer	1.65e-05	0.000215	CcSEcCtD
Medroxyprogesterone Acetate—Constipation—Doxorubicin—ovarian cancer	1.64e-05	0.000214	CcSEcCtD
Medroxyprogesterone Acetate—Body temperature increased—Epirubicin—ovarian cancer	1.64e-05	0.000214	CcSEcCtD
Medroxyprogesterone Acetate—Abdominal pain—Epirubicin—ovarian cancer	1.64e-05	0.000214	CcSEcCtD
Medroxyprogesterone Acetate—Feeling abnormal—Doxorubicin—ovarian cancer	1.58e-05	0.000206	CcSEcCtD
Medroxyprogesterone Acetate—Gastrointestinal pain—Doxorubicin—ovarian cancer	1.57e-05	0.000204	CcSEcCtD
Medroxyprogesterone Acetate—Hypersensitivity—Epirubicin—ovarian cancer	1.53e-05	0.000199	CcSEcCtD
Medroxyprogesterone Acetate—Urticaria—Doxorubicin—ovarian cancer	1.53e-05	0.000199	CcSEcCtD
Medroxyprogesterone Acetate—Abdominal pain—Doxorubicin—ovarian cancer	1.52e-05	0.000198	CcSEcCtD
Medroxyprogesterone Acetate—Body temperature increased—Doxorubicin—ovarian cancer	1.52e-05	0.000198	CcSEcCtD
Medroxyprogesterone Acetate—Asthenia—Epirubicin—ovarian cancer	1.49e-05	0.000194	CcSEcCtD
Medroxyprogesterone Acetate—Pruritus—Epirubicin—ovarian cancer	1.47e-05	0.000191	CcSEcCtD
Medroxyprogesterone Acetate—Diarrhoea—Epirubicin—ovarian cancer	1.42e-05	0.000185	CcSEcCtD
Medroxyprogesterone Acetate—Hypersensitivity—Doxorubicin—ovarian cancer	1.42e-05	0.000184	CcSEcCtD
Medroxyprogesterone Acetate—Asthenia—Doxorubicin—ovarian cancer	1.38e-05	0.000179	CcSEcCtD
Medroxyprogesterone Acetate—Dizziness—Epirubicin—ovarian cancer	1.37e-05	0.000179	CcSEcCtD
Medroxyprogesterone Acetate—Pruritus—Doxorubicin—ovarian cancer	1.36e-05	0.000177	CcSEcCtD
Medroxyprogesterone Acetate—Vomiting—Epirubicin—ovarian cancer	1.32e-05	0.000172	CcSEcCtD
Medroxyprogesterone Acetate—Diarrhoea—Doxorubicin—ovarian cancer	1.32e-05	0.000171	CcSEcCtD
Medroxyprogesterone Acetate—Rash—Epirubicin—ovarian cancer	1.31e-05	0.00017	CcSEcCtD
Medroxyprogesterone Acetate—Dermatitis—Epirubicin—ovarian cancer	1.31e-05	0.00017	CcSEcCtD
Medroxyprogesterone Acetate—Headache—Epirubicin—ovarian cancer	1.3e-05	0.000169	CcSEcCtD
Medroxyprogesterone Acetate—Dizziness—Doxorubicin—ovarian cancer	1.27e-05	0.000165	CcSEcCtD
Medroxyprogesterone Acetate—Nausea—Epirubicin—ovarian cancer	1.23e-05	0.000161	CcSEcCtD
Medroxyprogesterone Acetate—Vomiting—Doxorubicin—ovarian cancer	1.22e-05	0.000159	CcSEcCtD
Medroxyprogesterone Acetate—Rash—Doxorubicin—ovarian cancer	1.21e-05	0.000158	CcSEcCtD
Medroxyprogesterone Acetate—Dermatitis—Doxorubicin—ovarian cancer	1.21e-05	0.000157	CcSEcCtD
Medroxyprogesterone Acetate—Headache—Doxorubicin—ovarian cancer	1.2e-05	0.000157	CcSEcCtD
Medroxyprogesterone Acetate—ESR1—Integrated Breast Cancer Pathway—TP53—ovarian cancer	1.17e-05	0.000336	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Gene Expression—YAP1—ovarian cancer	1.17e-05	0.000334	CbGpPWpGaD
Medroxyprogesterone Acetate—HSD3B2—Metabolism—PTEN—ovarian cancer	1.16e-05	0.000332	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Integrated Pancreatic Cancer Pathway—MAPK1—ovarian cancer	1.16e-05	0.000331	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Integrated Pancreatic Cancer Pathway—EGFR—ovarian cancer	1.16e-05	0.000331	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—Gene Expression—YAP1—ovarian cancer	1.15e-05	0.000329	CbGpPWpGaD
Medroxyprogesterone Acetate—Nausea—Doxorubicin—ovarian cancer	1.14e-05	0.000149	CcSEcCtD
Medroxyprogesterone Acetate—AKR1C3—Disease—CAV1—ovarian cancer	1.13e-05	0.000324	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—PPP1CC—ovarian cancer	1.13e-05	0.000324	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling by ERBB4—HRAS—ovarian cancer	1.11e-05	0.000319	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—Generic Transcription Pathway—ESR1—ovarian cancer	1.11e-05	0.000319	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Integrated Pancreatic Cancer Pathway—KRAS—ovarian cancer	1.09e-05	0.000313	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—PPP2R1A—ovarian cancer	1.08e-05	0.000309	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Disease—IL6ST—ovarian cancer	1.07e-05	0.000307	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling by ERBB4—IL6—ovarian cancer	1.07e-05	0.000306	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Integrated Pancreatic Cancer Pathway—AKT1—ovarian cancer	1.06e-05	0.000305	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—PARP1—ovarian cancer	1.05e-05	0.0003	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Disease—APC—ovarian cancer	1.03e-05	0.000295	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—SIDS Susceptibility Pathways—IL6—ovarian cancer	1.03e-05	0.000295	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Gene Expression—PGR—ovarian cancer	1.02e-05	0.000292	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism of lipids and lipoproteins—FASN—ovarian cancer	1.01e-05	0.000289	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism of lipids and lipoproteins—YAP1—ovarian cancer	1.01e-05	0.000288	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Integrated Pancreatic Cancer Pathway—PIK3CA—ovarian cancer	1e-05	0.000288	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—Gene Expression—PGR—ovarian cancer	1e-05	0.000287	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Generic Transcription Pathway—MYC—ovarian cancer	1e-05	0.000287	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Gene Expression—PPP2R1A—ovarian cancer	9.96e-06	0.000286	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Integrated Breast Cancer Pathway—AKT1—ovarian cancer	9.89e-06	0.000284	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling by ERBB4—AKT1—ovarian cancer	9.84e-06	0.000282	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Integrated Pancreatic Cancer Pathway—TP53—ovarian cancer	9.71e-06	0.000278	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Metabolism—CAV1—ovarian cancer	9.47e-06	0.000272	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Gene Expression—PARP1—ovarian cancer	9.46e-06	0.000271	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—CYTB—ovarian cancer	9.39e-06	0.000269	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—Gene Expression—PARP1—ovarian cancer	9.32e-06	0.000267	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Gene Expression—ESR1—ovarian cancer	9.26e-06	0.000265	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism of lipids and lipoproteins—CYP1B1—ovarian cancer	9.18e-06	0.000263	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Disease—PIK3CD—ovarian cancer	9.06e-06	0.00026	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	9.05e-06	0.000259	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Metabolism—PIK3CG—ovarian cancer	8.63e-06	0.000247	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—HDAC6—ovarian cancer	8.56e-06	0.000245	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—TERT—ovarian cancer	8.56e-06	0.000245	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—PPP2R1A—ovarian cancer	8.5e-06	0.000244	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—PPP1CC—ovarian cancer	8.21e-06	0.000235	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—BRIP1—ovarian cancer	8.21e-06	0.000235	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism of lipids and lipoproteins—FASN—ovarian cancer	8.2e-06	0.000235	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Integrated Pancreatic Cancer Pathway—AKT1—ovarian cancer	8.2e-06	0.000235	CbGpPWpGaD
Medroxyprogesterone Acetate—HSD3B2—Metabolism—PIK3CA—ovarian cancer	8.16e-06	0.000234	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Disease—ERBB2—ovarian cancer	8e-06	0.000229	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—CAV1—ovarian cancer	7.92e-06	0.000227	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Disease—PIK3CB—ovarian cancer	7.89e-06	0.000226	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Disease—MTOR—ovarian cancer	7.89e-06	0.000226	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—NME2—ovarian cancer	7.82e-06	0.000224	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Gene Expression—PPP2R1A—ovarian cancer	7.67e-06	0.00022	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—CYTB—ovarian cancer	7.64e-06	0.000219	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—ESR1—ovarian cancer	7.63e-06	0.000219	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Generic Transcription Pathway—MYC—ovarian cancer	7.62e-06	0.000218	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Metabolism—PIK3CD—ovarian cancer	7.58e-06	0.000217	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—YAP1—ovarian cancer	7.58e-06	0.000217	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—Gene Expression—PPP2R1A—ovarian cancer	7.56e-06	0.000217	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—IL6ST—ovarian cancer	7.51e-06	0.000215	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism of lipids and lipoproteins—CYP1B1—ovarian cancer	7.47e-06	0.000214	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—XIAP—ovarian cancer	7.42e-06	0.000213	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Disease—CDKN1B—ovarian cancer	7.41e-06	0.000212	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—SMARCA4—ovarian cancer	7.23e-06	0.000207	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—APC—ovarian cancer	7.21e-06	0.000207	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—PIK3CG—ovarian cancer	7.21e-06	0.000207	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—EREG—ovarian cancer	7.06e-06	0.000202	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Gene Expression—ESR1—ovarian cancer	7.05e-06	0.000202	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Disease—CTNNB1—ovarian cancer	7e-06	0.000201	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Disease—PTEN—ovarian cancer	6.82e-06	0.000196	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—TERT—ovarian cancer	6.75e-06	0.000194	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—PPP1CC—ovarian cancer	6.68e-06	0.000191	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—BRIP1—ovarian cancer	6.68e-06	0.000191	CbGpPWpGaD
Medroxyprogesterone Acetate—HSD3B2—Metabolism—AKT1—ovarian cancer	6.67e-06	0.000191	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—PGR—ovarian cancer	6.62e-06	0.00019	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Metabolism—PIK3CB—ovarian cancer	6.61e-06	0.000189	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—PIK3CD—ovarian cancer	6.34e-06	0.000182	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—CAV1—ovarian cancer	6.25e-06	0.000179	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—PARP1—ovarian cancer	6.15e-06	0.000176	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Disease—STAT3—ovarian cancer	6.1e-06	0.000175	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Disease—NRAS—ovarian cancer	6.09e-06	0.000174	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—ESR1—ovarian cancer	6.02e-06	0.000173	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	5.98e-06	0.000171	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—IL6ST—ovarian cancer	5.92e-06	0.00017	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Generic Transcription Pathway—MYC—ovarian cancer	5.87e-06	0.000168	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Disease—MAPK3—ovarian cancer	5.83e-06	0.000167	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—Generic Transcription Pathway—MYC—ovarian cancer	5.78e-06	0.000166	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Metabolism—PTEN—ovarian cancer	5.71e-06	0.000164	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—PIK3CG—ovarian cancer	5.69e-06	0.000163	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—APC—ovarian cancer	5.69e-06	0.000163	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Disease—MYC—ovarian cancer	5.67e-06	0.000162	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—ERBB2—ovarian cancer	5.6e-06	0.000161	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Disease—MAPK1—ovarian cancer	5.55e-06	0.000159	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Disease—EGFR—ovarian cancer	5.54e-06	0.000159	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—PIK3CB—ovarian cancer	5.53e-06	0.000158	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—MTOR—ovarian cancer	5.53e-06	0.000158	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—YAP1—ovarian cancer	5.5e-06	0.000158	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	5.45e-06	0.000156	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—Gene Expression—ESR1—ovarian cancer	5.35e-06	0.000153	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—CXCL8—ovarian cancer	5.31e-06	0.000152	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Disease—KRAS—ovarian cancer	5.24e-06	0.00015	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—CDKN1B—ovarian cancer	5.19e-06	0.000149	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—CASP3—ovarian cancer	5.08e-06	0.000146	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—IL2—ovarian cancer	5.08e-06	0.000146	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—CYTB—ovarian cancer	5.04e-06	0.000144	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—PIK3CD—ovarian cancer	5e-06	0.000143	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—PPP2R1A—ovarian cancer	4.99e-06	0.000143	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Gene Expression—MAPK3—ovarian cancer	4.95e-06	0.000142	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—CCND1—ovarian cancer	4.95e-06	0.000142	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—CTNNB1—ovarian cancer	4.9e-06	0.00014	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	4.87e-06	0.00014	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Gene Expression—MYC—ovarian cancer	4.82e-06	0.000138	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Disease—PIK3CA—ovarian cancer	4.81e-06	0.000138	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—MMP9—ovarian cancer	4.8e-06	0.000138	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	4.79e-06	0.000137	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—PTEN—ovarian cancer	4.78e-06	0.000137	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—FASN—ovarian cancer	4.49e-06	0.000129	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—YAP1—ovarian cancer	4.48e-06	0.000128	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Disease—HRAS—ovarian cancer	4.45e-06	0.000128	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	4.43e-06	0.000127	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—ERBB2—ovarian cancer	4.42e-06	0.000127	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—SLC5A5—ovarian cancer	4.41e-06	0.000127	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—BRIP1—ovarian cancer	4.4e-06	0.000126	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—PPP1CC—ovarian cancer	4.4e-06	0.000126	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—PIK3CB—ovarian cancer	4.36e-06	0.000125	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—MTOR—ovarian cancer	4.36e-06	0.000125	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—VEGFA—ovarian cancer	4.31e-06	0.000124	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—STAT3—ovarian cancer	4.27e-06	0.000122	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—SLC2A1—ovarian cancer	4.26e-06	0.000122	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—NRAS—ovarian cancer	4.26e-06	0.000122	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Disease—IL6—ovarian cancer	4.26e-06	0.000122	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—CXCL8—ovarian cancer	4.19e-06	0.00012	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	4.17e-06	0.00012	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—CDKN1B—ovarian cancer	4.09e-06	0.000117	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—CYP1B1—ovarian cancer	4.09e-06	0.000117	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—MAPK3—ovarian cancer	4.08e-06	0.000117	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Metabolism—PIK3CA—ovarian cancer	4.03e-06	0.000116	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—CASP3—ovarian cancer	4.01e-06	0.000115	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—IL2—ovarian cancer	4e-06	0.000115	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—MYC—ovarian cancer	3.97e-06	0.000114	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—TERT—ovarian cancer	3.96e-06	0.000114	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Disease—AKT1—ovarian cancer	3.93e-06	0.000113	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—CCND1—ovarian cancer	3.9e-06	0.000112	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	3.9e-06	0.000112	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—MAPK1—ovarian cancer	3.88e-06	0.000111	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—EGFR—ovarian cancer	3.88e-06	0.000111	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—CTNNB1—ovarian cancer	3.87e-06	0.000111	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—MMP9—ovarian cancer	3.79e-06	0.000109	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Gene Expression—MAPK3—ovarian cancer	3.77e-06	0.000108	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—PTEN—ovarian cancer	3.77e-06	0.000108	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Gene Expression—MYC—ovarian cancer	3.67e-06	0.000105	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—KRAS—ovarian cancer	3.67e-06	0.000105	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—CAV1—ovarian cancer	3.67e-06	0.000105	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—FASN—ovarian cancer	3.65e-06	0.000105	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—PPP2R1A—ovarian cancer	3.62e-06	0.000104	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	3.61e-06	0.000103	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—SLC5A5—ovarian cancer	3.59e-06	0.000103	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—IL6ST—ovarian cancer	3.48e-06	9.96e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—SLC2A1—ovarian cancer	3.47e-06	9.94e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—VEGFA—ovarian cancer	3.4e-06	9.76e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	3.4e-06	9.74e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—STAT3—ovarian cancer	3.37e-06	9.66e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—PIK3CA—ovarian cancer	3.37e-06	9.66e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—ABCB1—ovarian cancer	3.37e-06	9.65e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—NRAS—ovarian cancer	3.36e-06	9.64e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—PIK3CG—ovarian cancer	3.34e-06	9.57e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—APC—ovarian cancer	3.34e-06	9.57e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Gene Expression—AKT1—ovarian cancer	3.34e-06	9.57e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—CYP1B1—ovarian cancer	3.33e-06	9.53e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—TYMS—ovarian cancer	3.3e-06	9.47e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Metabolism—AKT1—ovarian cancer	3.29e-06	9.44e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—TP53—ovarian cancer	3.26e-06	9.34e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—MAPK3—ovarian cancer	3.22e-06	9.23e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—MYC—ovarian cancer	3.13e-06	8.98e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—HRAS—ovarian cancer	3.12e-06	8.94e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—MAPK1—ovarian cancer	3.06e-06	8.78e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—EGFR—ovarian cancer	3.06e-06	8.78e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—IL6—ovarian cancer	2.98e-06	8.55e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—YAP1—ovarian cancer	2.95e-06	8.47e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—PPP2R1A—ovarian cancer	2.95e-06	8.45e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—PIK3CD—ovarian cancer	2.94e-06	8.42e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	2.94e-06	8.41e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Gene Expression—MAPK3—ovarian cancer	2.91e-06	8.33e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—KRAS—ovarian cancer	2.89e-06	8.29e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—Gene Expression—MAPK3—ovarian cancer	2.86e-06	8.2e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Gene Expression—MYC—ovarian cancer	2.83e-06	8.1e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—Gene Expression—MYC—ovarian cancer	2.78e-06	7.98e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—AKT1—ovarian cancer	2.75e-06	7.89e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—ABCB1—ovarian cancer	2.74e-06	7.85e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—TYMS—ovarian cancer	2.69e-06	7.71e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—CAV1—ovarian cancer	2.66e-06	7.63e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—PIK3CA—ovarian cancer	2.66e-06	7.62e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—ERBB2—ovarian cancer	2.59e-06	7.43e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—TP53—ovarian cancer	2.57e-06	7.37e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—MTOR—ovarian cancer	2.56e-06	7.34e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—PIK3CB—ovarian cancer	2.56e-06	7.34e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Gene Expression—AKT1—ovarian cancer	2.54e-06	7.29e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	2.54e-06	7.29e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—HRAS—ovarian cancer	2.46e-06	7.05e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—CXCL8—ovarian cancer	2.46e-06	7.05e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—PIK3CG—ovarian cancer	2.43e-06	6.95e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—FASN—ovarian cancer	2.41e-06	6.9e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—CDKN1B—ovarian cancer	2.4e-06	6.88e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—SLC5A5—ovarian cancer	2.37e-06	6.79e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—CASP3—ovarian cancer	2.35e-06	6.75e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—IL6—ovarian cancer	2.35e-06	6.75e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—IL2—ovarian cancer	2.35e-06	6.74e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—CCND1—ovarian cancer	2.29e-06	6.57e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—SLC2A1—ovarian cancer	2.29e-06	6.56e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—CTNNB1—ovarian cancer	2.27e-06	6.5e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—MMP9—ovarian cancer	2.22e-06	6.38e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—PTEN—ovarian cancer	2.21e-06	6.34e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—CYP1B1—ovarian cancer	2.19e-06	6.29e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—AKT1—ovarian cancer	2.17e-06	6.22e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—CAV1—ovarian cancer	2.17e-06	6.21e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—PIK3CD—ovarian cancer	2.13e-06	6.11e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	2.07e-06	5.94e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—VEGFA—ovarian cancer	2e-06	5.73e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—STAT3—ovarian cancer	1.98e-06	5.67e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—PIK3CG—ovarian cancer	1.97e-06	5.66e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—NRAS—ovarian cancer	1.97e-06	5.66e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Gene Expression—AKT1—ovarian cancer	1.96e-06	5.62e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—PPP2R1A—ovarian cancer	1.95e-06	5.58e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—Gene Expression—AKT1—ovarian cancer	1.93e-06	5.53e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—MAPK3—ovarian cancer	1.89e-06	5.42e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—PIK3CB—ovarian cancer	1.86e-06	5.33e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—MYC—ovarian cancer	1.84e-06	5.27e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—ABCB1—ovarian cancer	1.81e-06	5.18e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—MAPK1—ovarian cancer	1.8e-06	5.15e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—EGFR—ovarian cancer	1.8e-06	5.15e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—TYMS—ovarian cancer	1.77e-06	5.08e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—PIK3CD—ovarian cancer	1.74e-06	4.97e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—KRAS—ovarian cancer	1.7e-06	4.87e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—PTEN—ovarian cancer	1.61e-06	4.6e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—PIK3CA—ovarian cancer	1.56e-06	4.47e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—PIK3CB—ovarian cancer	1.51e-06	4.34e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—TP53—ovarian cancer	1.51e-06	4.33e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—HRAS—ovarian cancer	1.44e-06	4.14e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—CAV1—ovarian cancer	1.43e-06	4.1e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—IL6—ovarian cancer	1.38e-06	3.96e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—PTEN—ovarian cancer	1.31e-06	3.75e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—PIK3CG—ovarian cancer	1.3e-06	3.73e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—AKT1—ovarian cancer	1.27e-06	3.65e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—PIK3CD—ovarian cancer	1.14e-06	3.28e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—PIK3CA—ovarian cancer	1.13e-06	3.25e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—PIK3CB—ovarian cancer	9.98e-07	2.86e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—AKT1—ovarian cancer	9.26e-07	2.65e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—PIK3CA—ovarian cancer	9.22e-07	2.64e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—PTEN—ovarian cancer	8.62e-07	2.47e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—AKT1—ovarian cancer	7.53e-07	2.16e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—PIK3CA—ovarian cancer	6.08e-07	1.74e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—AKT1—ovarian cancer	4.97e-07	1.42e-05	CbGpPWpGaD
